
Quarterly report 2025-Q3
added 11-12-2025
Lixte Biotechnology Holdings Net Debt 2011-2026 | LIXT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Lixte Biotechnology Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -5.07 M | -2.6 M | -4.27 M | -1.31 M | -200 K | -25.3 K | -44.4 K | -480 K | -1.66 M | -10 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10 K | -5.07 M | -1.57 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Veracyte
VCYT
|
-323 M | $ 30.92 | -5.73 % | $ 2.43 B | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Avid Bioservices
CDMO
|
17.5 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
65 M | $ 12.67 | -9.24 % | $ 1.92 B | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 321.51 | -2.03 % | $ 42.1 B | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
-9.78 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-7.29 M | $ 1.09 | - | $ 22.4 M | ||
|
Enochian Biosciences
ENOB
|
645 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Equillium
EQ
|
-29.6 M | $ 1.91 | -7.28 % | $ 109 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 19.46 | -0.36 % | $ 910 M | ||
|
Amarin Corporation plc
AMRN
|
-189 M | $ 14.23 | -2.97 % | $ 5.91 B | ||
|
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
-141 M | $ 45.99 | -3.28 % | $ 4.14 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.33 | -2.81 % | $ 830 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M |